Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

Vivtex's early low profile was a strategic choice to mature its technology and precisely define its value to partners. This 'figuring it out' period allowed them to avoid making a premature public splash with offerings they might later have to retract, ensuring a stronger, more coherent market entry.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

Arcus navigated its capital-intensive early years by using strategic collaborations to bring in over $1 billion in largely non-dilutive funding. This approach allowed the company to reach late-stage clinical milestones and generate valuable data, bridging the gap to a point where public market investors could see tangible value.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.

The landmark partnership with Novo Nordisk wasn't won through a sales pitch. It was the result of a multi-year scientific relationship built on transparency. Consistently presenting progress, including failures, at conferences established deep institutional trust and credibility that proved invaluable.